MIRXES-B (02629) surged nearly 8% in early trading, with gains moderating to 2.48% by the time of writing, reaching HK$53.8 and a turnover of HK$18.29 million. On November 18, Mirxes announced the signing of a memorandum of understanding with Walvax Biotechnology (300142.SZ) to deepen collaboration in molecular diagnostics and vaccine development, jointly expanding into the ASEAN and global markets. This partnership signifies a strategic synergy between a leader in precision diagnostics and a top-tier vaccine developer, laying a solid foundation for an RNA-centric preventive and precision medicine platform. Notably, in October, the company's flagship product, GASTROClear, received approval from China's National Medical Products Administration (NMPA), becoming the world's first and only molecular diagnostic IVD product approved for gastric cancer screening. A research report by Founder Securities highlighted that this milestone not only marks the company's "zero-to-one" commercialization breakthrough but also introduces a new valuation logic. The approval positions MIRXES-B to tap into China's vast gastric cancer screening market, serving as a key near-term performance catalyst.